基于一期临床试验取得的积极成果,Anixa Biosciences(ANIX)已将其乳腺癌疫苗研发项目推进至二期临床阶段。与此同时,Cytovance生物制药公司被选定负责该疫苗的cGMP(现行药品生产质量管理规范)生产工作。
基于一期临床试验取得的积极成果,Anixa Biosciences(ANIX)已将其乳腺癌疫苗研发项目推进至二期临床阶段。与此同时,Cytovance生物制药公司被选定负责该疫苗的cGMP(现行药品生产质量管理规范)生产工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.